{"id":"NCT00525044","sponsor":"Boehringer Ingelheim","briefTitle":"Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat","officialTitle":"Double-blind, Randomized, Placebo-controlled Trial to Investigate the Efficacy and Tolerance of Ambroxol Lozenges 20 mg in the Treatment of Sore Throat in Patients With Acute Viral Pharyngitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08-01","primaryCompletion":"2008-01-01","completion":"2008-01-01","firstPosted":"2007-09-05","resultsPosted":"2019-07-11","lastUpdate":"2019-07-11"},"enrollment":249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pharyngitis"],"interventions":[{"type":"DRUG","name":"Ambroxol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Control","type":"PLACEBO_COMPARATOR"},{"label":"Ambroxol","type":"EXPERIMENTAL"}],"summary":"The aim of this trial is to investigate the efficacy and tolerance of Ambroxol lozenges 20 mg in the treatment of sore throat in patients with acute viral pharyngitis.","primaryOutcome":{"measure":"Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline","timeFrame":"pre-dose baseline and 30, 60, 120, and 180 minutes","effectByArm":[{"arm":"Ambroxol Lozenges 20 mg","deltaMin":-0.4,"sd":0.02},{"arm":"Placebo","deltaMin":-0.34,"sd":0.02}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0156"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":[]}}